Loading clinical trials...
Loading clinical trials...
Pilot Study of NP-101 (TQ Formula) in Combination With Nivolumab and Ipilimumab in Advanced and Metastatic Extra-pulmonary Neuroendocrine Carcinomas (EP-NECAs)
Conditions
Interventions
NP-101 (TQ Formula)
Nivolumab (3mg/kg)
+1 more
Locations
1
United States
University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Start Date
December 15, 2022
Primary Completion Date
December 1, 2025
Completion Date
June 1, 2026
Last Updated
August 7, 2025
NCT05636618
NCT05969860
NCT05691465
NCT05058651
NCT05746208
NCT06424665
Lead Sponsor
Amr Mohamed MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions